Application of pedunculoside in preparation of medicine for inhibiting lung metastatic cancer

A technology of leucanthoside and metastatic cancer, which is applied in the field of medicine to achieve the effects of reducing release, alleviating pathological damage, and inhibiting the formation of

Pending Publication Date: 2022-05-31
GUANGXI UNIV OF CHINESE MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, no studies have shown that catechin glucoside is effective in the treatment of lung metastases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pedunculoside in preparation of medicine for inhibiting lung metastatic cancer
  • Application of pedunculoside in preparation of medicine for inhibiting lung metastatic cancer
  • Application of pedunculoside in preparation of medicine for inhibiting lung metastatic cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] The present invention will be further described in detail below with reference to the accompanying drawings, so that those skilled in the art can implement it with reference to the description.

[0028] It should be understood that terms such as "having", "comprising" and "including" as used herein do not exclude the presence or addition of one or more other elements or combinations thereof.

[0029] It should be noted that the experimental methods described in the following embodiments are conventional methods unless otherwise specified, and the reagents and materials can be obtained from commercial sources unless otherwise specified.

[0030] At present, EGFR-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs (such as gefitinib) are the first-line drugs for the treatment of EGFR-mutated and ALK gene fusion NSCLC by the FDA in 2015. It is of great significance in development and metastasis, but over time, some patients will develop acquired EGFR-TKI resistance, which ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of pedunculoside in preparation of a medicine for inhibiting lung metastatic cancer. The structural formula of the pedunculoside is shown in formula (I). The invention mainly discusses the inhibiting effect of the pedunculoside on lung metastasis in a mouse lung metastatic cancer model constructed by caudal vein injection B16-F10 cells; the action mechanism is possibly related to reduction of release of inflammatory factors in blood, inhibition of formation of pulmonary metastasis and reduction of pathological injury of lung tissues.

Description

technical field [0001] The present invention relates to the technical field of medicine. More specifically, the present invention relates to the application of analigoside in the preparation of a medicament for inhibiting lung metastases. Background technique [0002] Lung cancer is a highly malignant tumor and one of the most common types of cancer worldwide. In 2012, an estimated 1.8 million new lung cancer cases accounted for approximately 12.9% of all cancers diagnosed globally. According to the International Agency for Research on Cancer (IARC), there were 2.1 million new lung cancer cases globally in 2018, and lung cancer-related deaths rose to 1.8 million. Lung cancer is divided into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which account for approximately 80% and 20% of all lung cancer cases, respectively. Due to the limitations of early effective screening and asymptomatic clinical manifestations, 70% to 80% of lung cancer p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7024A61K36/185A61P35/04A61P11/00
CPCA61K31/7024A61K36/185A61P35/04A61P11/00Y02A50/30
Inventor 高红伟苑仁祎坤黄莉婷
Owner GUANGXI UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap